Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing. It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.

Expanding Access to Lifesaving Therapies in AFMET

In the Africa-Midde East, Turkey (AFMET) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its commercialized biosimilars.

Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the AFMET region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia.

Focused on Making a Meaningful Difference in Turkey

Turkey is among the key focus countries for Biocon Biologics in the AFMET region, where biosimilars adoption is steadily increasing. The company is focused on broadening access to biosimilars for the benefit of patients and improving healthcare outcomes in Turkey. Since 2018, Biocon Biologics has partnered with Abdi Ibrahim, Turkey’s leading pharmaceutical company, addressing the needs of thousands of breast cancer patients in the country. Canhera (Trastuzumab) is Biocon Biologics’ sole commercialized product in Turkey.

Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner has further strengthened Biocon Biologics’ commercial presence in Turkey. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in Turkey, making a meaningful impact on patients’ lives.

In Turkey, Trastuzumab is commercialized by our partner Abdi Ibrahim.